Lithogenic Potential of Ureaplasma in Chronic Prostatitis

2020 ◽  
pp. 1-6
Author(s):  
Vittorio Magri ◽  
Gianpaolo Perletti ◽  
Konstantinos Stamatiou ◽  
Emanuele Montanari ◽  
Alberto Trinchieri

<b><i>Introduction:</i></b> The role of <i>Ureaplasma</i> spp. (UPs) in the pathogenesis of chronic prostatitis is debated. The lithogenic potential of UPs could be a risk factor for the development of chronic prostatitis. <b><i>Methods:</i></b> A total of 143 patients with identification of UPs were retrospectively selected from a database including patients with prostatitis-like symptoms who were studied according to the same protocol including clinical, microbiological and microscopic evaluation, and transrectal prostate ultrasound. A control group of patients with negative UPs was considered including 393 with chronic bacterial prostatitis (CBP), 42 patients with <i>Chlamydia trachomatis</i> (CT), and 781 patients with chronic pelvic pain syndrome. UPs and <i>Mycoplasma hominis</i> (MH) were identified using a semiquantitative assay. <b><i>Results:</i></b> Calcifications were observed more frequently in patients with UPs (64%) than in patients with CBP without UPs (39%), CT infection (37%), and chronic pelvic pain syndrome (29%) (<i>p</i> &#x3c; 0.0001). UPs were isolated in VB1 alone in 35 patients (urethral UPs), in expressed prostatic secretion (EPS) or post-massage urine (VB3) or sperm in 77 patients (prostatic UPs) and associated with other pathogens in 31 patients (associated UPs). Calcifications were more frequent in prostatic UPs (71%) and associated UPs (73%) than in urethral UPs (34%). Mean NIH-CPSI scores were not significantly different between groups, although mean WBC counts of sperm of patients with urethral UPs were significantly lower than in patients with prostatic UPs (<i>p</i> = 0.000) and associated UPs (<i>p</i> = 0.002). <b><i>Conclusions:</i></b> UPs identification in the urogenital fluids is related to higher rates of prostate calcifications. The ability of UPs to promote the formation of calcifications could be related to the chronicization of prostate infection. In particular, the presence of UPs in VB3/EPS/sperm is associated with higher rates of calcifications and high WBC sperm counts, suggesting a partial or full causative role of UPs in the pathogenesis of this disease.

2011 ◽  
Vol 12 (4) ◽  
pp. 297-303 ◽  
Author(s):  
Brandon A. Mahal ◽  
Jeffrey M. Cohen ◽  
Stephen A. Allsop ◽  
John B. Moore ◽  
Salman F. Bhai ◽  
...  

2005 ◽  
Vol 6 (4) ◽  
pp. 300-306 ◽  
Author(s):  
Vi N. Hua ◽  
Daniel H. Williams ◽  
Anthony J. Schaeffer

2009 ◽  
Vol 58 (12) ◽  
pp. 829-836 ◽  
Author(s):  
Marco Dellabella ◽  
Giulio Milanese ◽  
Sandra Sigala ◽  
Gianluca d’Anzeo ◽  
Nicola Arrighi ◽  
...  

2007 ◽  
Vol 78 (2) ◽  
pp. 97-105 ◽  
Author(s):  
Shaun Wen Huey Lee ◽  
Men Long Liong ◽  
Kah Hay Yuen ◽  
Yee Vonne Liong ◽  
John N. Krieger

2016 ◽  
Vol 10 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Simon Allen ◽  
Ivan G Aghajanyan

Background: Type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is the most common type of prostatitis. Patients and methods: We ascertained the effect of ‘thermobalancing’ therapy (TT; using Dr Allen’s therapeutic device (DATD)) on CP/CPPS. We measured National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume (PV), and maximum urinary flow rate (Qmax) in one group of 45 patients who underwent TT and a control group that did not have TT, and compared these parameters between groups. Results: Baseline evaluation (pretreatment) of both groups showed no significant difference with regard to age, NIH-CPSI score, PV or Qmax. Pain score decreased in both groups but, in the treatment group, the difference between scores was considerably higher (8.72:1) than that of the non-treatment group. TT decreased quality of life (QoL) significantly whereas, in the control group, it decreased QoL slightly. TT reduced PV significantly whereas, in the control group, PV increased. TT increased Qmax significantly in CP/CPPS patients whereas, in the control group, TT did not elicit a significant change in Qmax. Conclusions: Six-month TT with DATD: (a) reduces CP/CPPS symptoms and improves QoL; (b) reduces PV; (c) increases Qmax. TT could be effective treatment for CP/CPPS.


Sign in / Sign up

Export Citation Format

Share Document